iOrganBio appoints Karol Jarzabek as Chief Operating Officer
pharmafile | February 12, 2026 | Appointment | Manufacturing and Production | iOrganBio
iOrganBio has announced the appointment of Karol Jarzabek as Chief Operating Officer (COO).
Jarzabek specialises in operational management and business transformation, and has established experience in the deployment of AI-powered systems. Jarzabek most recently served as Vice President of Portfolio Operations at QHP Capital, during which time he was responsible for value creation in 13 life sciences and pharmaceutical companies.
Prior to that, Jarzabek held various leadership positions at Azurity Pharmaceuticals, including Vice President of Strategic Finance and President of Established Brands.
The company recently launched its CellForge platform, which is designed to tackle difficulties in human cell manufacturing through AI.
In his role as COO, Jarzabek will lead a diverse variety of initiatives, including operational execution and regulatory alignment.
Daniel Deluab, co-founder and CEO of iOrganBio, said: “Karol brings extensive experience designing operational structures and aligning teams across life science businesses, with a proven track record of translating strategy into measurable results.”
Jarzabek added: “What impressed me about iOrganBio is how intentionally the platform was designed from the start. There is strong integration between the science and data infrastructure. The team is applying true engineering rigour to complex biological systems, creating a foundation that can actually scale. This approach has the potential to fundamentally change how therapies are developed for patients.”
iOrganBio is a company specialising in intelligent cell manufacturing.
